7 results match your criteria: "Stanford University School of Medicine and Cancer Institute[Affiliation]"
Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.
J Eur Acad Dermatol Venereol
September 2024
University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.
Article Synopsis
- - Mycosis fungoides (MF) and Sézary syndrome (SS) are skin-related lymphomas that can significantly affect quality of life (HRQL), and a study found that patients treated with mogamulizumab reported better HRQL compared to those on vorinostat.
- - A study involving 372 adults with relapsed MF or SS revealed that their HRQL was notably lower than normal averages, particularly affecting their emotional state and functioning due to factors like itchiness and overall health.
- - Key demographic factors such as being female, younger, and having specific health conditions were linked to worse HRQL across different assessments, emphasizing the need to address these issues in patient care.
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Eur J Cancer
May 2021
Department of Dermatology, Skin Cancer Center, University Hospital Zürich, Gloriastrasse 31, 8091, Zürich, Switzerland. Electronic address:
Introduction: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study.
Methods: Baseline CD30 levels and large-cell transformation (LCT) status were centrally reviewed in patients with previously-treated CD30-positive MF using ≥2 skin biopsies obtained at screening; eligible patients required ≥1 biopsy with ≥10% CD30 expression.
Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease.
Am Heart J
October 2015
Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA.
Unlabelled: Guidelines recommend coronary artery bypass graft (CABG) surgery over percutaneous coronary intervention (PCI) for the treatment of 3-vessel coronary artery disease (3-VD). The inferior results of PCI demonstrated by previous large randomized trials comparing PCI and CABG might be explained by the use of suboptimal stent technology and by the lack of fractional flow reserve (FFR) guidance of PCI.
Trial Design: The objective of this investigator-initiated, multicenter, randomized clinical trial is to investigate whether FFR-guided PCI with new-generation stents is noninferior to CABG in patients with 3-VD, not including the left main coronary artery.
Tumor Ulceration Does Not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults.
J Invest Dermatol
December 2015
Department of Research, Cancer Prevention Institute of California, Fremont, California, USA; Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA.
Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the Women's Health Initiative.
Prev Med
December 2014
Stanford University, Department of Dermatology, Redwood City, CA, United States; Stanford University School of Medicine and Cancer Institute, Stanford, CA, United States.
Objective: Evidence for the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on non-melanoma skin cancer (NMSC) risk is inconsistent. We prospectively examined whether regular, inconsistent, or no/low-use of NSAIDs is associated with lower NMSC risk among 54,728 postmenopausal Caucasian women in the Women's Health Initiative Observational Study enrolled between 1993 and 1998.
Methods: Logistic regression models were used to assess odds of NMSC after adjusting for skin type, sun exposure history and indication for NSAID use.
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Br J Cancer
February 2014
Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.
Background: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC).
Methods: This single arm, multicentre phase II trial enrolled patients with previously untreated, locally advanced or metastatic non-squamous NSCLC. Patients received intravenous ziv-aflibercept 6 mg kg(-1), pemetrexed 500 mg m(-2), and cisplatin 75 mg m(-2), every 21 days for up to six cycles.
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative.
Cancer
April 2013
Stanford University School of Medicine and Cancer Institute, Stanford, California, USA.
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with decreased risk of gastric, colorectal, and breast cancer. However, the impact of NSAIDs on the risk of melanoma has been inconsistent. The authors evaluated the association between NSAID use and cutaneous melanoma risk in the Women's Health Initiative (WHI) Observational Study (OS).
View Article and Find Full Text PDF